Evidence map›Paper›PMID 28393897›Full record

ArticleScientific reports2017

Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity.

Silvia Sacchi, Vito De Novellis, Giovanna Paolone, Tommaso Nuzzo, Monica Iannotta, Carmela Belardo, Marta Squillace, Paolo Bolognesi, Elena Rosini, Zoraide Motta and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. On the regulation of human D-aspartate oxidase.Protein science : a publication of the Protein Society · 2023
    Article
  13. Amino acid metabolism in health and disease.Signal transduction and targeted therapy · 2023
    Review
  14. Review
  15. Review
  16. Efficacy of Olanzapine in Anxiety Dimension of Schizophrenia: A Systematic Review of Randomized Controlled Trials.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Silvia SacchiDipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.
Vito De NovellisDepartment of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy.
Giovanna PaoloneDepartment of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy.
Tommaso NuzzoLaboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.
Monica IannottaDepartment of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy.
Carmela BelardoDepartment of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy.
Marta SquillaceLaboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.
Paolo BolognesiDepartment of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy.
Elena RosiniDipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.
Zoraide MottaDipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.
Martina FrassinetiDepartment of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy.
Alessandro BertolinoDepartment of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, 70121, Bari, Italy.
Loredano PollegioniDipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.
Michele MorariDepartment of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy.
Sabatino MaioneDepartment of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy.
Francesco ErricoLaboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.
Alessandro UsielloLaboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.
University of Campania "Luigi Vanvitelli" · ITUniversity of Ferrara · ITPolitecnico di Milano · ITUniversity of Insubria · ITUniversity of Naples Federico II · ITCeinge Biotecnologie Avanzate (Italy) · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

D-aspartate levels in the brain are regulated by the catabolic enzyme D-aspartate oxidase (DDO). D-aspartate activates NMDA receptors, and influences brain connectivity and behaviors relevant to schizophrenia in animal models. In addition, recent evidence reported a significant reduction of D-aspartate levels in the post-mortem brain of schizophrenia-affected patients, associated to higher DDO activity. In the present work, microdialysis experiments in freely moving mice revealed that exogenously administered D-aspartate efficiently cross the blood brain barrier and stimulates L-glutamate efflux in the prefrontal cortex (PFC). Consistently, D-aspartate was able to evoke L-glutamate release in a preparation of cortical synaptosomes through presynaptic stimulation of NMDA, mGlu5 and AMPA/kainate receptors. In support of a potential therapeutic relevance of D-aspartate metabolism in schizophrenia, in vitro enzymatic assays revealed that the second-generation antipsychotic olanzapine, differently to clozapine, chlorpromazine, haloperidol, bupropion, fluoxetine and amitriptyline, inhibits the human DDO activity. In line with in vitro evidence, chronic systemic administration of olanzapine induces a significant extracellular release of D-aspartate and L-glutamate in the PFC of freely moving mice, which is suppressed in Ddo knockout animals. These results suggest that the second-generation antipsychotic olanzapine, through the inhibition of DDO activity, increases L-glutamate release in the PFC of treated mice.

Indexed as

AnimalsBenzodiazepinesClozapineD-Aspartate OxidaseDose-Response Relationship, DrugEnzyme ActivationGlutamic AcidHumansMaleMiceMice, KnockoutN-MethylaspartateOlanzapinePrefrontal CortexReceptors, N-Methyl-D-AspartateSelective Serotonin Reuptake InhibitorsBenzodiazepinesClozapineD-Aspartate OxidaseGlutamic AcidN-MethylaspartateOlanzapineReceptors, N-Methyl-D-AspartateSelective Serotonin Reuptake Inhibitors

Identifiers

PMID28393897
PMCPMC5385520
OpenAlexW2606021389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.